Ocata Therapeutics Inc fka OCAT

[NYPharmer1]

Part 5

Growing Legislative Support
CA Prop. 71 provides $3.0 billion in funding over 10 years for stem cell research, with preference given to research that is ineligible for NIH funding.
Other states (e.g., NJ, CT, FL, IL, MD, NY, MA, and MO) have passed or proposed similar initiatives.
Political landscape moving in positive direction for stem cell industry starting with President Obama new embryonic stem cell directive initiated January 2009.

Highly Experienced Leadership

Read this article regarding ACTC's Chief Scientific Officer here: http://discovermagazine.com/2008/sep/19-fighting-for-the-right-to-clone/?searchterm=Dr.%20Lanza

"Whether defying the dean of the University of Pennsylvania Schl. of Medicine so he could publish a book on world health or challenging the titans of cosmology, Robert Lanza has never followed the script. It’s no wonder, then, that this renegade doctor would lead the charge into medicine’s most controversial turf: the creation of cloned embryos for therapy and the engineering of spare human parts."